TG Therapeutics, Azer-Cel, Azercabtagene Zapreleucel, Progressive Multiple Sclerosis, MS, CAR T-Cell Therapy, Allogeneic CAR T, CD19, Phase 1 Clinical Trial, TG-Azercel-101

NEW YORK, N.Y. — October 23, 2026 TG Therapeutics (NASDAQ: TGTX) announced initial Phase 1 results for azercabtagene zapreleucel...